Skip to content

Study · Animal study (in vivo) · mouse · 2017

16 results

Intranasal Cerebrolysin Attenuates Learning and Memory Impairments in D-galactose-Induced Senescence in Mice.

Pourmemar E, Majdi A, Haramshahi M, Talebi M, Karimi P, Sadigh-Eteghad S

Experimental gerontology25 Nov 2016Cited by 54 (Europe PMC)

PMID27894939 (opens in a new tab)DOI10.1016/j.exger.2016.11.011 (opens in a new tab)PepBankPUB-27894939
Publisher pagePubMedAsk about this study
Jump to 16 results

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: Publisher copyright. Results still quote short attributed sentences.

Results from this study16

16 results from studies that gave the peptide. No result from this study comes from people.

  1. 01AnimalAnimal study (in vivo)Efficacy outcome

    In aged mice receiving d-galactose, intraperitoneal Cerebrolysin increased locomotor activity.

    In plain wordsIn aged mice receiving d-galactose, intraperitoneal Cerebrolysin increased locomotor activity.

    Peptide
    Cerebrolysin
    Outcome
    IncreaseLocomotor activity
    Study

    mousen: not reported in source

    D-galactose-induced senescence
    Outcome group
    Exercise and physical function · Nervous system and cognition
    Studied dose
    5 ml/kg · intraperitoneal · eight weeksAs given in this study (mouse).

    Source sentences

    Summary
    5 ml/kg/i.p. dose of CBL increased the locomotor activity but, 1 ml/kg/i.p. dose didn't show detectable behavioural or molecular effects on aged mice.
    1 context sentence
    Summary · context
    For this purpose, CBL (1, 2.5, 5 ml/kg/i.p.) or (1 ml/kg/i.n.), were administrated daily in d-galactose-received (100 mg/kg/subcutaneous (s.c.)) mice model of aging for eight weeks.
  2. 02AnimalAnimal study (in vivo)Efficacy outcome

    In aged mice receiving d-galactose, intraperitoneal Cerebrolysin had no detectable behavioral or molecular effects.

    In plain wordsIn aged mice receiving d-galactose, intraperitoneal Cerebrolysin had no detectable behavioral or molecular effects.

    Peptide
    Cerebrolysin
    Outcome
    No significant changeBehavioral and molecular effects
    Study

    mousen: not reported in source

    D-galactose-induced senescence
    Outcome group
    Neuroprotection · Nervous system and cognition
    Studied dose
    1 ml/kg · intraperitoneal · eight weeksAs given in this study (mouse).

    Source sentences

    Summary
    5 ml/kg/i.p. dose of CBL increased the locomotor activity but, 1 ml/kg/i.p. dose didn't show detectable behavioural or molecular effects on aged mice.
    1 context sentence
    Summary · context
    For this purpose, CBL (1, 2.5, 5 ml/kg/i.p.) or (1 ml/kg/i.n.), were administrated daily in d-galactose-received (100 mg/kg/subcutaneous (s.c.)) mice model of aging for eight weeks.
  3. 03AnimalAnimal study (in vivo)Efficacy outcome

    In mice receiving d-galactose, intraperitoneal Cerebrolysin attenuated spatial memory impairment.

    In plain wordsIn mice receiving d-galactose, intraperitoneal Cerebrolysin reduced spatial memory impairment.

    Peptide
    Cerebrolysin
    Outcome
    DecreaseSpatial memory impairment
    Study

    mousen: not reported in source

    D-galactose-induced senescence
    Outcome group
    Cognition and memory · Nervous system and cognition
    Studied dose
    2.5 ml/kg · intraperitoneal · eight weeksAs given in this study (mouse).

    Source sentences

    Summary
    Treatment with 2.5 ml/kg/i.p. and 1 ml/kg/i.n. doses attenuated d-galactose-impaired spatial and recognition memories.
    1 context sentence
    Summary · context
    For this purpose, CBL (1, 2.5, 5 ml/kg/i.p.) or (1 ml/kg/i.n.), were administrated daily in d-galactose-received (100 mg/kg/subcutaneous (s.c.)) mice model of aging for eight weeks.
  4. 04AnimalAnimal study (in vivo)Efficacy outcome

    In mice receiving d-galactose, intranasal Cerebrolysin attenuated spatial memory impairment.

    In plain wordsIn mice receiving d-galactose, intranasal Cerebrolysin reduced spatial memory impairment.

    Peptide
    Cerebrolysin
    Outcome
    DecreaseSpatial memory impairment
    Study

    mousen: not reported in source

    D-galactose-induced senescence
    Outcome group
    Cognition and memory · Nervous system and cognition
    Studied dose
    1 ml/kg · intranasal · eight weeksAs given in this study (mouse).

    Source sentences

    Summary
    Treatment with 2.5 ml/kg/i.p. and 1 ml/kg/i.n. doses attenuated d-galactose-impaired spatial and recognition memories.
    1 context sentence
    Summary · context
    For this purpose, CBL (1, 2.5, 5 ml/kg/i.p.) or (1 ml/kg/i.n.), were administrated daily in d-galactose-received (100 mg/kg/subcutaneous (s.c.)) mice model of aging for eight weeks.
  5. 05AnimalAnimal study (in vivo)Efficacy outcome

    In mice receiving d-galactose, intraperitoneal Cerebrolysin attenuated recognition memory impairment.

    In plain wordsIn mice receiving d-galactose, intraperitoneal Cerebrolysin reduced recognition memory impairment.

    Peptide
    Cerebrolysin
    Outcome
    DecreaseRecognition memory impairment
    Study

    mousen: not reported in source

    D-galactose-induced senescence
    Outcome group
    Cognition and memory · Nervous system and cognition
    Studied dose
    2.5 ml/kg · intraperitoneal · eight weeksAs given in this study (mouse).

    Source sentences

    Summary
    Treatment with 2.5 ml/kg/i.p. and 1 ml/kg/i.n. doses attenuated d-galactose-impaired spatial and recognition memories.
    1 context sentence
    Summary · context
    For this purpose, CBL (1, 2.5, 5 ml/kg/i.p.) or (1 ml/kg/i.n.), were administrated daily in d-galactose-received (100 mg/kg/subcutaneous (s.c.)) mice model of aging for eight weeks.
  6. 06AnimalAnimal study (in vivo)Efficacy outcome

    In mice receiving d-galactose, intranasal Cerebrolysin attenuated recognition memory impairment.

    In plain wordsIn mice receiving d-galactose, intranasal Cerebrolysin reduced recognition memory impairment.

    Peptide
    Cerebrolysin
    Outcome
    DecreaseRecognition memory impairment
    Study

    mousen: not reported in source

    D-galactose-induced senescence
    Outcome group
    Cognition and memory · Nervous system and cognition
    Studied dose
    1 ml/kg · intranasal · eight weeksAs given in this study (mouse).

    Source sentences

    Summary
    Treatment with 2.5 ml/kg/i.p. and 1 ml/kg/i.n. doses attenuated d-galactose-impaired spatial and recognition memories.
    1 context sentence
    Summary · context
    For this purpose, CBL (1, 2.5, 5 ml/kg/i.p.) or (1 ml/kg/i.n.), were administrated daily in d-galactose-received (100 mg/kg/subcutaneous (s.c.)) mice model of aging for eight weeks.
  7. 07AnimalAnimal study (in vivo)Mechanism

    In aged mice receiving d-galactose, intraperitoneal Cerebrolysin increased blood antioxidant biomarkers.

    In plain wordsIn aged mice receiving d-galactose, intraperitoneal Cerebrolysin increased blood antioxidant biomarkers.

    Peptide
    Cerebrolysin
    Outcome
    IncreaseBlood antioxidant biomarkers
    Study

    mousen: not reported in source

    D-galactose-induced senescence
    Outcome group
    Aging markers · Whole body
    Studied dose
    2.5 ml/kg · intraperitoneal · eight weeksAs given in this study (mouse).

    Source sentences

    Summary
    Results showed an obvious increase in the antioxidant biomarkers and decrease in the malondialdehyde levels both in the blood and brain of aged mice in 2.5 ml/kg/i.p. dose, and only in the brain in 1 ml/kg/i.n. dose of CBL.
    1 context sentence
    Summary · context
    For this purpose, CBL (1, 2.5, 5 ml/kg/i.p.) or (1 ml/kg/i.n.), were administrated daily in d-galactose-received (100 mg/kg/subcutaneous (s.c.)) mice model of aging for eight weeks.
  8. 08AnimalAnimal study (in vivo)Mechanism

    In aged mice receiving d-galactose, intraperitoneal Cerebrolysin increased brain antioxidant biomarkers.

    In plain wordsIn aged mice receiving d-galactose, intraperitoneal Cerebrolysin increased brain antioxidant biomarkers.

    Peptide
    Cerebrolysin
    Outcome
    IncreaseBrain antioxidant biomarkers
    Study

    mousen: not reported in source

    D-galactose-induced senescence
    Outcome group
    Aging markers · Nervous system and cognition
    Studied dose
    2.5 ml/kg · intraperitoneal · eight weeksAs given in this study (mouse).

    Source sentences

    Summary
    Results showed an obvious increase in the antioxidant biomarkers and decrease in the malondialdehyde levels both in the blood and brain of aged mice in 2.5 ml/kg/i.p. dose, and only in the brain in 1 ml/kg/i.n. dose of CBL.
    1 context sentence
    Summary · context
    For this purpose, CBL (1, 2.5, 5 ml/kg/i.p.) or (1 ml/kg/i.n.), were administrated daily in d-galactose-received (100 mg/kg/subcutaneous (s.c.)) mice model of aging for eight weeks.
  9. 09AnimalAnimal study (in vivo)Mechanism

    In aged mice receiving d-galactose, intranasal Cerebrolysin increased antioxidant biomarkers only in the brain.

    In plain wordsIn aged mice receiving d-galactose, intranasal Cerebrolysin increased antioxidant biomarkers only in the brain.

    Peptide
    Cerebrolysin
    Outcome
    IncreaseBrain antioxidant biomarkers
    Study

    mousen: not reported in source

    D-galactose-induced senescence
    Outcome group
    Aging markers · Nervous system and cognition
    Studied dose
    1 ml/kg · intranasal · eight weeksAs given in this study (mouse).

    Source sentences

    Summary
    Results showed an obvious increase in the antioxidant biomarkers and decrease in the malondialdehyde levels both in the blood and brain of aged mice in 2.5 ml/kg/i.p. dose, and only in the brain in 1 ml/kg/i.n. dose of CBL.
    1 context sentence
    Summary · context
    For this purpose, CBL (1, 2.5, 5 ml/kg/i.p.) or (1 ml/kg/i.n.), were administrated daily in d-galactose-received (100 mg/kg/subcutaneous (s.c.)) mice model of aging for eight weeks.
  10. 10AnimalAnimal study (in vivo)Mechanism

    In aged mice receiving d-galactose, intraperitoneal Cerebrolysin decreased blood malondialdehyde levels.

    In plain wordsIn aged mice receiving d-galactose, intraperitoneal Cerebrolysin decreased blood malondialdehyde levels.

    Peptide
    Cerebrolysin
    Outcome
    DecreaseBlood malondialdehyde levels
    Study

    mousen: not reported in source

    D-galactose-induced senescence
    Outcome group
    Aging markers · Whole body
    Studied dose
    2.5 ml/kg · intraperitoneal · eight weeksAs given in this study (mouse).

    Source sentences

    Summary
    Results showed an obvious increase in the antioxidant biomarkers and decrease in the malondialdehyde levels both in the blood and brain of aged mice in 2.5 ml/kg/i.p. dose, and only in the brain in 1 ml/kg/i.n. dose of CBL.
    1 context sentence
    Summary · context
    For this purpose, CBL (1, 2.5, 5 ml/kg/i.p.) or (1 ml/kg/i.n.), were administrated daily in d-galactose-received (100 mg/kg/subcutaneous (s.c.)) mice model of aging for eight weeks.
  11. 11AnimalAnimal study (in vivo)Mechanism

    In aged mice receiving d-galactose, intraperitoneal Cerebrolysin decreased brain malondialdehyde levels.

    In plain wordsIn aged mice receiving d-galactose, intraperitoneal Cerebrolysin decreased brain malondialdehyde levels.

    Peptide
    Cerebrolysin
    Outcome
    DecreaseBrain malondialdehyde levels
    Study

    mousen: not reported in source

    D-galactose-induced senescence
    Outcome group
    Aging markers · Nervous system and cognition
    Studied dose
    2.5 ml/kg · intraperitoneal · eight weeksAs given in this study (mouse).

    Source sentences

    Summary
    Results showed an obvious increase in the antioxidant biomarkers and decrease in the malondialdehyde levels both in the blood and brain of aged mice in 2.5 ml/kg/i.p. dose, and only in the brain in 1 ml/kg/i.n. dose of CBL.
    1 context sentence
    Summary · context
    For this purpose, CBL (1, 2.5, 5 ml/kg/i.p.) or (1 ml/kg/i.n.), were administrated daily in d-galactose-received (100 mg/kg/subcutaneous (s.c.)) mice model of aging for eight weeks.
  12. 12AnimalAnimal study (in vivo)Mechanism

    In aged mice receiving d-galactose, intranasal Cerebrolysin decreased malondialdehyde levels only in the brain.

    In plain wordsIn aged mice receiving d-galactose, intranasal Cerebrolysin decreased malondialdehyde levels only in the brain.

    Peptide
    Cerebrolysin
    Outcome
    DecreaseBrain malondialdehyde levels
    Study

    mousen: not reported in source

    D-galactose-induced senescence
    Outcome group
    Aging markers · Nervous system and cognition
    Studied dose
    1 ml/kg · intranasal · eight weeksAs given in this study (mouse).

    Source sentences

    Summary
    Results showed an obvious increase in the antioxidant biomarkers and decrease in the malondialdehyde levels both in the blood and brain of aged mice in 2.5 ml/kg/i.p. dose, and only in the brain in 1 ml/kg/i.n. dose of CBL.
    1 context sentence
    Summary · context
    For this purpose, CBL (1, 2.5, 5 ml/kg/i.p.) or (1 ml/kg/i.n.), were administrated daily in d-galactose-received (100 mg/kg/subcutaneous (s.c.)) mice model of aging for eight weeks.
  13. 13AnimalAnimal study (in vivo)Efficacy outcome

    In aged mice receiving d-galactose, intraperitoneal Cerebrolysin showed anti-apoptotic effects.

    In plain wordsIn aged mice receiving d-galactose, intraperitoneal Cerebrolysin showed anti-apoptotic effects.

    Peptide
    Cerebrolysin
    Outcome
    DecreaseHippocampal apoptosis
    Study

    mousen: not reported in source

    D-galactose-induced senescence
    Outcome group
    Neuroprotection · Nervous system and cognition
    Studied dose
    2.5 ml/kg · intraperitoneal · eight weeksAs given in this study (mouse).

    Source sentences

    Summary
    Anti-apoptotic effects also were seen in the same dose/rout of CBL administration in aged animals.
    3 context sentences
    Summary · context
    Results showed an obvious increase in the antioxidant biomarkers and decrease in the malondialdehyde levels both in the blood and brain of aged mice in 2.5 ml/kg/i.p. dose, and only in the brain in 1 ml/kg/i.n. dose of CBL.
    Summary · context
    Apoptosis rate in the hippocampus was evaluated by TUNEL staining of brain tissue.
    Summary · context
    For this purpose, CBL (1, 2.5, 5 ml/kg/i.p.) or (1 ml/kg/i.n.), were administrated daily in d-galactose-received (100 mg/kg/subcutaneous (s.c.)) mice model of aging for eight weeks.
  14. 14AnimalAnimal study (in vivo)Efficacy outcome

    In aged mice receiving d-galactose, intranasal Cerebrolysin showed anti-apoptotic effects.

    In plain wordsIn aged mice receiving d-galactose, intranasal Cerebrolysin showed anti-apoptotic effects.

    Peptide
    Cerebrolysin
    Outcome
    DecreaseHippocampal apoptosis
    Study

    mousen: not reported in source

    D-galactose-induced senescence
    Outcome group
    Neuroprotection · Nervous system and cognition
    Studied dose
    1 ml/kg · intranasal · eight weeksAs given in this study (mouse).

    Source sentences

    Summary
    Anti-apoptotic effects also were seen in the same dose/rout of CBL administration in aged animals.
    3 context sentences
    Summary · context
    Results showed an obvious increase in the antioxidant biomarkers and decrease in the malondialdehyde levels both in the blood and brain of aged mice in 2.5 ml/kg/i.p. dose, and only in the brain in 1 ml/kg/i.n. dose of CBL.
    Summary · context
    Apoptosis rate in the hippocampus was evaluated by TUNEL staining of brain tissue.
    Summary · context
    For this purpose, CBL (1, 2.5, 5 ml/kg/i.p.) or (1 ml/kg/i.n.), were administrated daily in d-galactose-received (100 mg/kg/subcutaneous (s.c.)) mice model of aging for eight weeks.
  15. 15AnimalAnimal study (in vivo)Mechanism

    In aged mice receiving d-galactose, intranasal Cerebrolysin did not increase blood antioxidant biomarkers.

    In plain wordsIn aged mice receiving d-galactose, intranasal Cerebrolysin did not increase blood antioxidant biomarkers.

    Peptide
    Cerebrolysin
    Outcome
    No significant changeBlood antioxidant biomarkers
    Study

    mousen: not reported in source

    D-galactose-induced senescence
    Outcome group
    Aging markers · Whole body
    Studied dose
    1 ml/kg · intranasal · eight weeksAs given in this study (mouse).

    Source sentences

    Summary
    Results showed an obvious increase in the antioxidant biomarkers and decrease in the malondialdehyde levels both in the blood and brain of aged mice in 2.5 ml/kg/i.p. dose, and only in the brain in 1 ml/kg/i.n. dose of CBL.
    1 context sentence
    Summary · context
    For this purpose, CBL (1, 2.5, 5 ml/kg/i.p.) or (1 ml/kg/i.n.), were administrated daily in d-galactose-received (100 mg/kg/subcutaneous (s.c.)) mice model of aging for eight weeks.
  16. 16AnimalAnimal study (in vivo)Mechanism

    In aged mice receiving d-galactose, intranasal Cerebrolysin did not decrease blood malondialdehyde levels.

    In plain wordsIn aged mice receiving d-galactose, intranasal Cerebrolysin did not decrease blood malondialdehyde levels.

    Peptide
    Cerebrolysin
    Outcome
    No significant changeBlood malondialdehyde levels
    Study

    mousen: not reported in source

    D-galactose-induced senescence
    Outcome group
    Aging markers · Whole body
    Studied dose
    1 ml/kg · intranasal · eight weeksAs given in this study (mouse).

    Source sentences

    Summary
    Results showed an obvious increase in the antioxidant biomarkers and decrease in the malondialdehyde levels both in the blood and brain of aged mice in 2.5 ml/kg/i.p. dose, and only in the brain in 1 ml/kg/i.n. dose of CBL.
    1 context sentence
    Summary · context
    For this purpose, CBL (1, 2.5, 5 ml/kg/i.p.) or (1 ml/kg/i.n.), were administrated daily in d-galactose-received (100 mg/kg/subcutaneous (s.c.)) mice model of aging for eight weeks.

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

  1. Version 2Current

    14 Oct 2026, 05:02 UTC

    Study results updated

  2. Version 1

    14 Oct 2026, 01:46 UTC

    First added · source update from Europe PMC

Subjects

Terms as the source lists them.

PepBank is a research reference. Talk to a doctor before you use any peptide.